Brainstorm reports Q3 net loss $1.2M; withdraws NurOwn BLA for ALS, cuts 30% headcount

BRAINSTORM CELL THERAPEUTICS INC.

Withdrew BLA for NurOwn in ALS after FDA advisory committee vote; FDA invites expedited meeting for path forward.
Strategic realignment reduces headcount ~30%, targets cutting total resource consumption by half.
Cash, equivalents, and short-term deposits at $1.4M as of Sep 30, 2023, down from $3M at Dec 31, 2022.
Net loss for Q3 2023 was $1.2M ($0.03 per share) vs. $6.9M ($0.19 per share) in Q3 2022.
Raised ~$7.5M gross in July 2023 registered direct offering with a single institutional investor.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BRAINSTORM CELL THERAPEUTICS INC. reported the quarter ended September 30, 2023 results: net income Net loss for the three months ended September 30, 2023 was approximately $1.2 million, EPS Net loss per share for the three months ended September 30, 2023 and 2022 was $0.03 and $0.19, respectively.

Period: the quarter ended September 30, 2023
Net income: Net loss for the three months ended September 30, 2023 was approximately $1.2 million
EPS: Net loss per share for the three months ended September 30, 2023 and 2022 was $0.03 and $0.19, respectively
Result: reported results

Exact text from the filing

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-117678

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.